Clinical Trial Update: Efficacy Study on the Transfer of Adenovirus With the CD40 Ligand Gene (AdcuCD40L) to Patients With Esophageal Carcinoma [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial investigating AdcuCD40L (an adenovirus carrying the CD40 ligand gene) for esophageal cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Cancer

Drugs mentioned

• AdcuCD40L

Snippet

Sponsor: Weill Medical College of Cornell University | Conditions: Esophageal Neoplasms | Phase 1, Phase 2 | Status: WITHDRAWN